Printer Friendly

Acumen Pharmaceuticals Inc. Announces Milestone Achievement in Collaboration With Merck & Co., Inc.

SOUTH SAN FRANCISCO, Calif. -- Acumen Pharmaceuticals Inc., a leading pre-clinical biotech company working in Alzheimer's therapeutics, today announced that its collaboration with Merck & Co., Inc. has achieved a $5 million milestone in the antibody program. The milestone was triggered by certain development activities.

The two companies signed a license agreement in 2003 to research and develop disease-modifying therapeutic drugs for Alzheimer's disease and other memory-related disorders. Under the terms of the original agreement, Merck obtained an exclusive license to research and develop antibody products, an option to develop vaccine products and certain diagnostic rights. In November, Merck amended the collaboration agreement to include an exclusive license grant to Merck for the diagnostic related rights.

"Merck continues to demonstrate why they are an excellent partner. This program has advanced so rapidly and so well because of the first class team Merck has deployed. We are excited by the results this collaboration has achieved, and are optimistic about its clinical prospects," said David Summa, President & CEO of Acumen.

"Merck is committed to developing disease modifying therapeutics for Alzheimer's. The Acumen collaboration has generated promising antibodies and we look forward to advancing them to the clinic," said Ken Koblan, Ph.D. Vice President, Neuroscience Research at Merck Research Laboratories. "Collaborations with biotech companies continue to be a vital part of Merck's strategy. We think the Acumen collaboration is an excellent example of how well biotech-pharmaceutical collaborations can work."

About Acumen

Acumen Pharmaceuticals Inc. (www.acumenpharm.com) is a venture-backed, pre-clinical biotech company focused on developing the first effective therapeutics and diagnostics for Alzheimer's disease and other memory-related disorders. Founded in 1996, Acumen owns or has licensed certain important patents underlying the ADDL mechanism now widely believed to cause Alzheimer's disease. Acumen has two small molecule programs at the lead chemistry stage of development in the Alzheimer's. NeuroVentures LLC and the Biotechnology Value Fund are investors in the company.
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jan 22, 2007
Words:315
Previous Article:Generics In The United States Report Includes Detailed Data On Market Size And Segmentation, Plus Textual Analysis Of The Key Trends And Competitive...
Next Article:Offshore Competition and Inventive Wiper Systems Challenge Wiper Refills and Arms Segment.
Topics:


Related Articles
Vical to receive a milestone payment from Merck as DNA vaccine candidate enters clinical trials.
IMCLONE SYSTEMS AND MERCK KGaA EXTEND COLLABORATION FOR THERAPEUTIC CANCER VACCINES.
Shaman Pharmaceuticals Announces Second Diabetes Drug Collaboration; Combined Agreements Infuse Over $25 million Committed Funding -- Plus Additional...
Merck & Co., Inc. and Karo Bio AB Enter Into a Strategic Alliance.
ICOS Corporation And Caprion Pharmaceuticals Enter Into Joint Development Collaboration.
Metabasis Therapeutics and Merck Announce Collaboration to Develop New Treatment for Diabetes, Hyperlipidemia and Obesity.
Caprion Pharmacueticals Announces New Collaboration with AstraZeneca.
Merck & Co., Inc. to Acquire GlycoFi, Inc.; Acquisition Enhances Merck Capabilities in Biologics Research and Development.
Acumen Pharmaceuticals Announces Amended Agreement with Merck to Include Exclusive Diagnostic Rights.
Merck & Co., Inc. and Lundbeck Discontinue Joint Development Program for Gaboxadol, an Investigational Compound for Insomnia.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters